Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01081249 · ClinicalTrials.gov registry record · Phase 4
Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting
A Phase 4 study of Anxiety and Behavior, sponsored by MacDonald, Kai, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01081249 is a Phase 4 study of Anxiety and Behavior that has completed, run by MacDonald, Kai, M.D.. The registered enrollment target is 18 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01081249, a Phase 4 study of Anxiety and Behavior, has completed, sponsored by MacDonald, Kai, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Subjects-currently in outpatient mental health care--will participate in 2 psychotherapy sessions, one with oxytocin spray and one with placebo spray. Sessions will be videotaped, and cortisol and heart rate will be measured. We hypothesize that oxytocin will have positive benefits on nonverbal behavior in the therapy session, as well as have positive effects on subjective anxiety, cortisol and heart rate.
Interventions
- DRUG Placebo then intranasal oxytocin
- DRUG Intranasal oxytocin then placebo
Study Locations (1)
California
- Kai MacDonald, MD 3368 2nd Ave Ste B - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01081249
The ClinicalTrials.gov registry entry for NCT01081249 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (96% lower). The listed sponsor is MacDonald, Kai, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Placebo then intranasal oxytocin is the first listed.
NCT01081249 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01081249 about?
NCT01081249 is a clinical study titled "Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting". Subjects-currently in outpatient mental health care--will participate in 2 psychotherapy sessions, one with oxytocin spray and one with placebo spray. Sessions will be videotaped, and cortisol and heart rate will be measured. We hypothesize that oxytocin will have positive benefits on nonverbal beha...
What is the current status of trial NCT01081249?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2008-12. Estimated completion is 2012-07.
What conditions does trial NCT01081249 study?
This clinical trial studies the following conditions: Anxiety, Behavior.
What interventions are being tested in trial NCT01081249?
The interventions under investigation include: Placebo then intranasal oxytocin (DRUG), Intranasal oxytocin then placebo (DRUG).
Who is sponsoring clinical trial NCT01081249?
This trial is sponsored by MacDonald, Kai, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01081249 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
RECRUITING · Phase 4
-
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
RECRUITING · Phase 4
-
Brain Stimulation & Generalized Anxiety Study
ACTIVE NOT RECRUITING · Phase 4
-
Epidiolex® for Anxiety in Pediatric Epilepsy
COMPLETED · Phase 4
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.